solute carrier family 2 member 12Genealiases: GLUT12 · GLUT8
Q-omics provides the consensus-scored SLC2A12 profile across patient tissues and cancer cell-line models. SLC2A12 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SLC2A12 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SLC2A12 RNA expression shows 17,781 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where SLC2A12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC2A12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC2A12 survival associations across molecular data types. SLC2A12 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC2A12 RNA expression–survival associations across cancer types. High SLC2A12 expression shows unfavorable associations in BLCA, KIRP, HNSC and TGCT, but favorable associations in COAD and LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for SLC2A12 RNA expression.
This table summarizes SLC2A12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC2A12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC2A12 shows lower tumor expression in KIRC, KIRP, BRCA, LUAD and THCA and higher tumor expression in COAD. The KIRC box plot shows higher SLC2A12 RNA expression in normal versus tumor tissue (log2 FC = −2.670, t-test p < 0.001).
This table shows molecular features associated with SLC2A12 in patient tissues and cancer cell lines. In patient samples, SLC2A12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC2A12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
